We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

120 hedge funds and large institutions have $252M invested in Sutro Biopharma in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $27K | Put options by funds: $5K

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

4% more funds holding

Funds holding: 115 → 120 (+5)

2% more capital invested

Capital invested by funds: $248M → $252M (+$4.09M)

0.35% less ownership

Funds ownership: 9.31% → 8.95% (-0.35%)

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
45
Reduced
37
Closed
13
Calls
$27K
Puts
$5K
Net Calls
+$22K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.9M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$3.99M
3
EP
Eversept Partners
New York
+$3.72M
4
Millennium Management
Millennium Management
New York
+$3.05M
5
KCM
Kynam Capital Management
New Jersey
+$2.98M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$9.1M
2
FLSM
Frazier Life Sciences Management
California
-$4.96M
3
Goldman Sachs
Goldman Sachs
New York
-$2M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$1.55M
5
RCMNY
Rubric Capital Management (New York)
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
51
Prudential Financial
New Jersey
$443K +$402K +8,080 +562%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$417K +$24.6K +495 +6%
TC
53
Tejara Capital
United Kingdom
$412K +$220K +4,420 +99%
AQR Capital Management
54
AQR Capital Management
Connecticut
$380K -$1.55M -31,200 -79%
Fidelity Investments
55
Fidelity Investments
Massachusetts
$370K -$20.2K -406 -5%
JP Morgan Chase
56
JP Morgan Chase
New York
$347K +$15.1K +304 +4%
SFI
57
Susquehanna Fundamental Investments
Pennsylvania
$339K – – –
AllianceBernstein
58
AllianceBernstein
Tennessee
$334K +$102K +2,041 +40%
PI
59
Putnam Investments
Massachusetts
$321K -$10.7K -215 -3%
Bank of America
60
Bank of America
North Carolina
$317K -$1.23M -24,711 -78%
Ohio Public Employees Retirement System (OPERS)
61
Ohio Public Employees Retirement System (OPERS)
Ohio
$287K – – –
Los Angeles Capital Management
62
Los Angeles Capital Management
California
$263K +$53.1K +1,067 +23%
Mirae Asset Global Investments
63
Mirae Asset Global Investments
South Korea
$211K -$40.9K -822 -15%
Barclays
64
Barclays
United Kingdom
$207K -$382K -7,665 -63%
D.E. Shaw & Co
65
D.E. Shaw & Co
New York
$189K -$570K -11,448 -74%
CIC
66
Cornercap Investment Counsel
Georgia
$168K +$747 +15 +0.4%
PCM
67
Prelude Capital Management
New York
$140K -$3.09K -62 -2%
UBS Group
68
UBS Group
Switzerland
$140K -$262K -5,264 -64%
AIG
69
American International Group
New York
$135K +$14.6K +293 +11%
American Century Companies
70
American Century Companies
Missouri
$133K +$68.9K +1,385 +94%
MIM
71
MetLife Investment Management
New Jersey
$132K – – –
Citadel Advisors
72
Citadel Advisors
Florida
$132K -$1.5M -30,084 -91%
VIA
73
Virtus Investment Advisers
Connecticut
$131K – – –
Deutsche Bank
74
Deutsche Bank
Germany
$130K -$24.6K -495 -15%
Wells Fargo
75
Wells Fargo
California
$128K -$112K -2,258 -45%
1 2
3
4 5

STRO Hedge Fund Activity: Q2 2023 in Review

120 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2023, worth a combined $252M — up 1.7% from $248M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new STRO positions and 13 closed out — a net gain of 5 holders — while 45 added to existing stakes and 37 trimmed.

The largest buyer was BlackRock, adding an estimated $4.9M. The largest seller was State Street, cutting an estimated $9.1M.

  • 120 institutional investors held Sutro Biopharma (STRO) as of Q2 2023, up from 115 in Q1 2023.
  • Funds reported $252M of Sutro Biopharma stock for Q2 2023, up 1.7% quarter-over-quarter.
  • 18 funds opened new Sutro Biopharma positions in Q2 2023 and 13 closed out, a net change of +5 holders.
  • The largest Sutro Biopharma buyer in Q2 2023 was BlackRock, an estimated $4.9M added.
  • The largest Sutro Biopharma seller in Q2 2023 was State Street, an estimated $9.1M sold.

Based on aggregated 13F filings for Q2 2023.